汇宇制药：公司两款产品获得境外上市许可

Core Viewpoint - The company, Huyou Pharmaceutical (688553), announced that its subsidiaries, Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd., have received marketing approvals for their products, injectable Parecoxib Sodium and injectable Pemetrexed Disodium, from the Dutch Medicines and Healthcare Products Regulatory Agency and the Saudi Arabian Health Products Regulatory Authority [1]. Group 1 - The company has successfully obtained marketing licenses for two injectable products [1] - The approvals were granted by regulatory authorities in the Netherlands and Saudi Arabia [1] - This development may enhance the company's market presence in Europe and the Middle East [1]